A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Good Samaritan Medical Center Delray, Florida Announces Prostate Biopsy Treatment Option with MRI Precision Targeting

September 2, 2020

Good Samaritan Medical Center Delray, Florida, is now offering MRI precision targeting for prostate biopsy guidance, a new tool for physicians to use to help men in the fight against prostate cancer.  The UroNav Fusion Biopsy System by Phillips is a fully MRI-compatible interventional device for Trans-Rectal Interventional MRI of the prostate gland.

Good Samaritan Medical Center notes it adjusts in six directions for precision targeting and works with DynaCAD prostate to provide less invasive, targeted guidance. The multiple directional adjustments help clinicians access all areas of the prostate gland.  Once adjusted, the device can be locked into position, providing added confidence to biopsy procedures.

“This equipment is ushering in a new era in how we treat our patients, and it is designed to give them highly accurate readings for prostate biopsies,” said Dr. Antonio Beltran, urologist and member of the medical staff at Good Samaritan Center.  “This new offering provides our patients with one of the latest advanced medical technologies in urology.”

The UroNav device is comprised of three simple components:

  • A baseplate that adapts to the MRI gantry.
  • A clampstand which connects to the baseplate and offers multiple precise adjustments for location targeting.
  • A sterile, single use needle sleeve which affixes to the clampstand and guides the biopsy needle to the targeted site.

“We are pleased to be able to offer this new technology to our patients, and further advance the robust offerings of our oncology program,” said Sheri Montgomery, chief executive officer for Good Samaritan Medical Center.  “After a cancer diagnosis, it is important for patients to be able to have access to the latest treatment options close to home, and we are committed to offering those kinds of services at Good Sam.”

Prostate cancer is common among American men.  The chances of getting prostate cancer may be affected by your age, race, family history and diet.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy